

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dexcel Pharma Technologies Ltd.</u> (Last) (First) (Middle) <u>10 HAKIDMA STREET</u> (Street) <u>YOKNEAM L3 2069200</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/12/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>Protalix BioTherapeutics, Inc. [PLX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>4,556,031</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Common Stock Purchase Warrants</u>	<u>03/11/2020</u>	<u>03/11/2025</u>	<u>Common Stock</u>	<u>2,816,901⁽¹⁾</u>	<u>2.36</u>	<u>D</u>	

1. Name and Address of Reporting Person* <u>Dexcel Pharma Technologies Ltd.</u> (Last) (First) (Middle) <u>10 HAKIDMA STREET</u> (Street) <u>YOKNEAM L3 2069200</u> (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Oren Dan</u> (Last) (First) (Middle) <u>1 DEXCEL STREET</u> (Street) <u>OR AKIVA L3 3060000</u> (City) (State) (Zip)
--

Explanation of Responses:

1. The warrants contain a blocker that prohibits the holder from exercising the warrants if such exercise will result in beneficial ownership of more than 9.99% of the Issuer's outstanding common shares by the warrant holder and its affiliates. Since the reporting persons' beneficial ownership percentage is over 9.99%, the warrants are currently not

exercisable.

/s/ Dexcel Pharma
Technologies Ltd. by Dan
Oren, Executive Chairman 02/16/2021

/s/ Dan Oren 02/16/2021

** Signature of Reporting
Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.